GeneDx Holdings Corp.

NasdaqGS:WGS Stock Report

Market Cap: US$1.9b

GeneDx Holdings Past Earnings Performance

Past criteria checks 0/6

GeneDx Holdings has been growing earnings at an average annual rate of 0.4%, while the Healthcare industry saw earnings growing at 5.3% annually. Revenues have been growing at an average rate of 5.1% per year.

Key information

0.4%

Earnings growth rate

128.0%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate5.1%
Return on equity-40.8%
Net Margin-31.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results

Nov 01
US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results

GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term

Oct 30

GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists

Oct 21

After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar

Oct 04
After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar

Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?

Aug 29
Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?

GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform

Aug 19

Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher

Jul 27
Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher

GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

Jun 12
GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing

Jun 06

Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

Apr 24
Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

Feb 23
GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

Feb 22
The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Dec 20
Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Nov 02
Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Nov 01
Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Sema4 names Kevin Feeley as CFO

Aug 26

Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Aug 20
Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 19
Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Sema4 Q2 2022 Earnings Preview

Aug 12

Sema4 Holdings, Big Data For Precision Medicine Solutions

Jul 18

Revenue & Expenses Breakdown

How GeneDx Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:WGS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24267-8316646
30 Jun 24244-11716549
31 Mar 24222-13517655
31 Dec 23203-17619558
30 Sep 23206-45922570
30 Jun 23236-49426869
31 Mar 23224-53332279
31 Dec 22235-54933886
30 Sep 22231-28035784
30 Jun 22191-17033289
31 Mar 22202-13125973
31 Dec 21212-245324105
30 Sep 21218-331328114
30 Jun 21214-420305115
31 Mar 21197-406291113
31 Dec 20179-24117373
31 Dec 19196-337835
31 Dec 18133-274921

Quality Earnings: WGS is currently unprofitable.

Growing Profit Margin: WGS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: WGS is unprofitable, but has reduced losses over the past 5 years at a rate of 0.4% per year.

Accelerating Growth: Unable to compare WGS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: WGS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.3%).


Return on Equity

High ROE: WGS has a negative Return on Equity (-40.83%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies